BidaskClub upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday.
Several other brokerages have also commented on FATE. ValuEngine raised shares of Fate Therapeutics from a buy rating to a strong-buy rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Fate Therapeutics from a sell rating to a hold rating in a research note on Tuesday, May 8th. Piper Jaffray Companies reiterated a top pick rating and set a $20.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, March 6th. Wedbush reiterated an outperform rating and set a $10.00 price objective (down from $19.00) on shares of Fate Therapeutics in a research note on Tuesday, March 6th. Finally, BMO Capital Markets boosted their price objective on shares of Fate Therapeutics from $7.00 to $20.00 and gave the stock an outperform rating in a research note on Tuesday, March 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the company’s stock. Fate Therapeutics has an average rating of Buy and an average target price of $15.00.
Shares of NASDAQ FATE opened at $11.56 on Tuesday. Fate Therapeutics has a 12 month low of $2.52 and a 12 month high of $14.45. The company has a quick ratio of 7.20, a current ratio of 7.20 and a debt-to-equity ratio of 0.22. The company has a market cap of $595.72 million, a PE ratio of -11.33 and a beta of 1.74.
Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Fate Therapeutics had a negative return on equity of 77.27% and a negative net margin of 1,143.99%. The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $1.82 million. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. research analysts expect that Fate Therapeutics will post -1.05 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new position in shares of Fate Therapeutics in the first quarter valued at $107,000. Raymond James & Associates purchased a new position in shares of Fate Therapeutics in the fourth quarter valued at $141,000. Algert Global LLC purchased a new position in shares of Fate Therapeutics in the first quarter valued at $172,000. Trexquant Investment LP purchased a new position in shares of Fate Therapeutics in the first quarter valued at $179,000. Finally, Barclays PLC boosted its stake in shares of Fate Therapeutics by 201.9% in the first quarter. Barclays PLC now owns 18,805 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 12,577 shares during the period. Institutional investors own 74.39% of the company’s stock.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.